Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(19/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(19/week)
News
United States
(594/week)
Manufacturing
(436/week)
Energy
(328/week)
Technology
(473/week)
Other Manufacturing
(362/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Eribulin
May 29, 2020
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer at ASCO 2020
Sep 24, 2019
Eisai Announces Data Presentations on KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin) at ESMO 2019
May 22, 2019
United States $20 Bn Breast Cancer Drug Market to 2025: 42 Marketed Drugs, 317 Drugs in Clinical Pipeline by Company, Phase, Drug Class & Patient Segment
May 16, 2019
Eisai Announces Data Presentations on Oncology Pipeline, including LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Investigational Combination Therapy at ASCO 2019
Mar 06, 2019
Real World Evidence on Use of Halaven® (eribulin mesylate) Injection Following CDK 4/6 Inhibitor to be Presented at 36th Annual Miami Breast Cancer Conference
Nov 27, 2018
Eisai to Present New Research on HALAVEN® (eribulin mesylate) Injection at 41st Annual San Antonio Breast Cancer Symposium
Oct 22, 2018
Halozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress
Oct 09, 2018
Eisai to Present LENVIMA® (lenvatinib) and HALAVEN® (eribulin) Data in a Variety of Advanced Cancers at ESMO 2018 Congress
Apr 09, 2018
Morphotek Announces Agreement to License its Proprietary Eribulin-Linker Payload to Bliss Biopharmaceutical Co., Ltd. for Development of a Therapeutic Antibody-Drug Conjugate (ADC)*
Feb 05, 2018
Eribulin Mesylate Nearly Doubles Overall Survival in Previously Treated Patients with Advanced Liposarcoma in Subanalysis Published in the Journal of Clinical Oncology
Jan 10, 2018
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Dec 08, 2017
Encouraging Updated Results from Phase 1b/2 Study Evaluating the Combination of Eribulin Mesylate and Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer Presented at the 2017 SABCS
Dec 07, 2017
Morphotek To Present Its Proprietary RESPECT(TM) Antibody-Drug Conjugate (ADC) Technology At The Upcoming Antibody Engineering & Therapeutics Conference In San Diego
Dec 04, 2017
Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression
Nov 13, 2017
Morphotek To Present Its Proprietary RESPECT(TM) Antibody Drug Conjugate (ADC) Technology At The Upcoming 9th Annual PEGS Europe In Lisbon
Oct 03, 2017
Eisai Inc. and Grupo Biotoscana Sign Exclusive Licensing Agreement for the Commercialization of Eisai's Oncology and Neurology Products throughout Latin America
Oct 03, 2017
Grupo Biotoscana and EISAI sign exclusive licensing agreement for four novel oncology and neurology products in Latin America
Sep 19, 2017
Morphotek To Present Preclinical Data On Antibody-Drug Conjugate MORAb-202 At The Upcoming 8th Annual World ADC In San Diego
Aug 31, 2017
Eisai to Present New Clinical Data in Variety of Advanced Cancers at the ESMO 2017 Congress
Jun 22, 2017
Eisai and Ewopharma Announce Commercial Partnership in Central Eastern Europe for Halaven®, Targretin® and Zonegran®
Latest News
May 3, 2024
Ratliff & Taylor Expands Executive Search Practice to Support Regional Demand and Growth
May 3, 2024
Bowman Closes On $100 Million Revolving Credit Agreement
May 3, 2024
Green Plains Reports First Quarter 2024 Financial Results
May 3, 2024
Fluor Reports First Quarter 2024 Results
May 3, 2024
Global Textiles Industry & Net Zero Attitudes and Challenges Research Study: Focus on Sustainability...
May 3, 2024
nVent Electric plc First Quarter 2024 Financial Results Available on Company’s Website
May 3, 2024
AdvanSix Announces First Quarter 2024 Financial Results
May 3, 2024
Atmus Filtration Technologies Reports First Quarter 2024 Results
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events